Please check your internet connection and try again.
# L-Ornithine L-Aspartate (Hepamerz)
## Overview
L-Ornithine L-Aspartate (LOLA) is an amino acid derivative used primarily in the management of hepatic encephalopathy. It is believed to reduce ammonia levels by promoting its conversion to urea and glutamine in the liver and peripheral tissues.
## Primary Indications
* Treatment of latent and overt hepatic encephalopathy (HE).
## Adult Dosing
* **Oral:** Typically 3-6 grams three times daily. Doses may be titrated based on patient response and ammonia levels.
* **Intravenous (IV):** 5 grams administered over 30 minutes, once or twice daily. Maximum IV dose is generally 10 grams per day. Specific dosing protocols may vary by institution.
## Pediatric Dosing
* Data on pediatric use is limited. Dosing should be individualized under specialist supervision.
## Dose Adjustments
* No specific dose adjustments are routinely recommended for renal or hepatic impairment, as the drug is metabolized by the liver and the metabolites are excreted by the kidneys. However, caution is advised in severe renal impairment due to potential accumulation of ornithine and aspartate.
## Contraindications
* Known hypersensitivity to L-ornithine L-aspartate or its components.
* Severe renal insufficiency.
* Pre-existing high levels of arginine (as LOLA can further increase arginine levels, potentially leading to hyperammonemia).
## Adverse Effects
* **Common:** Gastrointestinal upset (nausea, vomiting, diarrhea, abdominal pain).
* **Less Common:** Dizziness, headache, fatigue, skin rash.
* **Rare:** Renal stones (with long-term, high-dose use).
## Key Drug Interactions
* **Barbiturates and Benzodiazepines:** May potentiate the sedative effects.
* **Diuretics:** May increase the risk of hyperkalemia and hypermagnesemia when used concurrently with other drugs affecting electrolyte balance.
* **Folic Acid and Cyanocobalamin:** May enhance the efficacy of LOLA.
## Monitoring
* Serum ammonia levels.
* Liver function tests.
* Renal function.
* Electrolytes (especially potassium and magnesium).
* Clinical assessment for signs and symptoms of hepatic encephalopathy.
## Clinical Pearls
* LOLA is most effective when ammonia levels are elevated.
* Oral administration is preferred for long-term management. IV administration is typically used for acute management of severe HE.
* The effectiveness of LOLA in improving cognitive function in HE is variable and may be dependent on the severity of the underlying liver disease.
* Ensure adequate hydration and electrolyte balance, particularly in patients receiving IV LOLA.
***
*Disclaimer: This information is intended for healthcare professionals and should not replace individual clinical judgment or a thorough review of the most current prescribing information, including full prescribing details, warnings, and precautions, for L-Ornithine L-Aspartate. Dosing and administration should always be guided by local protocols and individual patient factors.*
